Kelly Lawrence W & Associates Inc. CA maintained its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,087 shares of the pharmaceutical company’s stock at the end of the second quarter. Kelly Lawrence W & Associates Inc. CA’s holdings in Vertex Pharmaceuticals were worth $2,718,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in the stock. Guardian Life Insurance Co. of America increased its position in Vertex Pharmaceuticals by 0.6% in the first quarter. Guardian Life Insurance Co. of America now owns 956 shares of the pharmaceutical company’s stock valued at $105,000 after buying an additional 6 shares in the last quarter. Elk Creek Partners LLC increased its position in Vertex Pharmaceuticals by 0.3% in the first quarter. Elk Creek Partners LLC now owns 3,120 shares of the pharmaceutical company’s stock valued at $341,000 after buying an additional 10 shares in the last quarter. Sowell Financial Services LLC increased its position in Vertex Pharmaceuticals by 0.8% in the first quarter. Sowell Financial Services LLC now owns 2,762 shares of the pharmaceutical company’s stock valued at $325,000 after buying an additional 23 shares in the last quarter. Capital Investment Advisory Services LLC increased its position in Vertex Pharmaceuticals by 0.4% in the first quarter. Capital Investment Advisory Services LLC now owns 6,463 shares of the pharmaceutical company’s stock valued at $707,000 after buying an additional 25 shares in the last quarter. Finally, First Manhattan Co. increased its position in Vertex Pharmaceuticals by 1.3% in the first quarter. First Manhattan Co. now owns 2,356 shares of the pharmaceutical company’s stock valued at $205,000 after buying an additional 31 shares in the last quarter. Hedge funds and other institutional investors own 93.13% of the company’s stock.

Vertex Pharmaceuticals Incorporated (VRTX) opened at 153.26 on Wednesday. The company has a market cap of $38.64 billion, a PE ratio of 147.22 and a beta of 1.77. The stock has a 50 day moving average of $140.44 and a 200-day moving average of $112.89. Vertex Pharmaceuticals Incorporated has a 12-month low of $71.46 and a 12-month high of $167.86.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.39 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.33. The company had revenue of $544.10 million during the quarter, compared to the consensus estimate of $489.95 million. Vertex Pharmaceuticals had a return on equity of 4.64% and a net margin of 12.05%. During the same quarter in the previous year, the company posted $0.24 EPS. Vertex Pharmaceuticals’s quarterly revenue was up 26.1% compared to the same quarter last year. On average, equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post $1.59 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Kelly Lawrence W & Associates Inc. CA Has $2,718,000 Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)” was originally published by Daily Political and is the property of of Daily Political. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/08/09/kelly-lawrence-w-associates-inc-ca-has-2718000-stake-in-vertex-pharmaceuticals-incorporated-nasdaqvrtx.html.

Several research firms have commented on VRTX. UBS AG reiterated a “buy” rating and issued a $135.00 price objective (up from $132.00) on shares of Vertex Pharmaceuticals in a report on Friday, May 19th. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Vertex Pharmaceuticals in a report on Sunday, April 30th. Stifel Nicolaus upped their price objective on shares of Vertex Pharmaceuticals from $130.00 to $154.00 and gave the company a “buy” rating in a report on Tuesday, July 18th. Robert W. Baird reiterated an “outperform” rating and issued a $171.00 price objective (up from $136.00) on shares of Vertex Pharmaceuticals in a report on Friday, July 21st. Finally, Cowen and Company reiterated a “market perform” rating and issued a $105.00 price objective on shares of Vertex Pharmaceuticals in a report on Thursday, July 6th. Five analysts have rated the stock with a hold rating, twenty-two have given a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $162.88.

In related news, CEO Jeffrey M. Leiden sold 147,101 shares of the company’s stock in a transaction on Friday, June 2nd. The stock was sold at an average price of $129.50, for a total value of $19,049,579.50. Following the sale, the chief executive officer now directly owns 312,142 shares of the company’s stock, valued at $40,422,389. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CMO Jeffrey Chodakewitz sold 573 shares of the company’s stock in a transaction on Monday, July 17th. The stock was sold at an average price of $129.85, for a total value of $74,404.05. Following the completion of the sale, the chief marketing officer now directly owns 123,084 shares in the company, valued at $15,982,457.40. The disclosure for this sale can be found here. Insiders sold 745,503 shares of company stock valued at $112,220,787 in the last quarter. Corporate insiders own 1.80% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.